Showing 1121-1130 of 1484 results for "".
- Johnson & Johnson Vision Appoints Carol Alexander, OD, Head, North America Vision Care Professional Relationshttps://modernod.com/news/johnson-johnson-vision-appoints-carol-alexander-od-head-north-america-vision-care-professional-relations/2479774/Carol Alexander, OD, has been appointed Head, North America Vision Care Professional Relations for Johnson & Johnson Vision. In this role, Carol will work to strengthen the relationship between Johnson & Johnson Vision and the optometric community in the US, w
- OD-OS Releases Software Update For the Computer-Guided Navilas 577s Laser Systemhttps://modernod.com/news/od-os-releases-software-update-for-the-computer-guided-navilas-577s-laser-system/2480112/OD-OS has released a comprehensive software update for the computer-guided Navilas 577s Laser System. New functionalities of software release 3.4 make the tissue-friendly treatment of retinal diseases using navigated microsecond laser pulses more intuitive, predictable, and reproducible, accordin
- FDA Approval Granted for Eyeris Novel Contact Lenshttps://modernod.com/news/fda-approval-granted-for-eyeris-novel-contact-lens/2476946/Eyeris, a Nashville, Tennessee start-up, announced that it has closed its second round of funding and secured FDA approval for their daily disposable contact lens, which will become available in
- Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Noregen for Retinal Diseaseshttps://modernod.com/news/caeregen-therapeutics-receives-14-million-phase-2-sbir-grant-from-nihnei-to-advance-development-of-regenerative-medicine-clinical-candidate-ctr-107-noregen-for-retinal-diseases/2481729/Caeregen Therapeutics announced that it has been awarded a $1.4 million phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen), a regenerative therapeutic for the treatme
- MeiraGTx Announces AAV-RPGR Granted Fast Track Designation by FDA for Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiencyhttps://modernod.com/news/meiragtx-announces-aav-rpgr-granted-fast-track-designation-by-fda-for-treatment-of-x-linked-retinitis-pigmentosa-due-to-rpgr-deficiency/2480212/MeiraGTx Limited, a clinical stage gene therapy company, announced that the FDA has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene. “XLRP is a devastating c
- OneSight Seeks Volunteer ODs for Charitable Clinicshttps://modernod.com/news/onesight-seeks-volunteer-ods-for-charitable-clinics/2479133/OneSight, which provides vision care access to more than 50 million people globally through charitable vision clinics and permanent vision centers, is in need of optical professionals to volunteer their skills to help reach the 1.1 billion people worldwide who lack access to eye exams and glasses
- CE-Mark Granted to deepeye Medical for AI Tool for Retinal Therapy Planninghttps://modernod.com/news/ce-mark-granted-to-deepeye-medical-for-ai-tool-for-retinal-therapy-planning/2482816/deepeye Medical has received CE Mark for its deepeye TPS¹ (Therapy Planning Support) platform. The Class IIa approval was made under the EU Medical Device Regulation (MDR 2017/745), following certification by the Notified Body
- Mobius Therapeutics Granted New US Patent for Injected Ophthalmic Mitomycin-Chttps://modernod.com/news/mobius-therapeutics-granted-new-us-patent-for-injected-ophthalmic-mitomycin-c/2481319/Mobius Therapeutics has been issued US Patent #11,540,977, "Injection Apparatus and Method of Use," protecting future applications of Mitosol, Mobius’ flagship product, particularly versus compounded, unapproved copies of Mitosol. “This is an important ad
- Prevent Blindness and Aerie Pharmaceuticals Partner to Offer New Glaucoma Research Granthttps://modernod.com/news/prevent-blindness-and-aerie-pharmaceuticals-partner-to-offer-new-glaucoma-research-grant/2480868/Research to Prevent Blindness (RPB) and Aerie Pharmaceuticals are partnering to provide early- to mid-career vision scientists with opportunities to pursue glaucoma research of unusual significance and promise. RPB announced the launch the RPB/David L. Epstein Career Advancem
- LayerBio Granted U.S. Patent for OcuRing Drug Delivery Platformhttps://modernod.com/news/layerbio-granted-us-patent-for-ocuring-drug-delivery-platform/2480486/LayerBio announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11,185,441. "This patent issuance marks an important milestone for the OcuRing platform and recognition of novelty and uniqueness of our drug delivery technology,&